Metformin Pharmconsul (Metformin Hydrochloride)

Metformin Hydrochloride reduces hepatic glucose output and increases peripheral insulin sensitivity. It does this by inhibiting mitochondrial complex I and activating AMP‑activated protein kinase, which together lower blood sugar without stimulating insulin secretion.

The dosage of Metformin Pharmconsul is individualized and set by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. The prescriber determines the appropriate starting dose and any subsequent adjustments.

Safety of Metformin Pharmconsul in pregnancy and lactation has not been fully established. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order, submit an enquiry on the Metformin Pharmconsul product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas, metformin does not stimulate insulin release and therefore carries a lower risk of hypoglycemia. It is considered first‑line therapy in most guidelines because of its efficacy, weight neutrality and cardiovascular safety profile.

Store Metformin Pharmconsul at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, heat and direct sunlight to maintain stability.

Metformin Pharmconsul is taken orally, usually with meals to reduce gastrointestinal irritation. Tablets should be swallowed whole with a full glass of water; they are not intended to be chewed, crushed or dissolved.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that may present with muscle pain, rapid breathing, abdominal discomfort or unusual fatigue. Other serious concerns include severe hypoglycemia when combined with insulin or sulfonylureas, and rare cases of hepatic dysfunction.

Metformin Pharmconsul should be avoided in patients with severe renal impairment, known hypersensitivity to metformin, acute or chronic metabolic acidosis, and in those undergoing radiographic contrast studies when renal function is compromised.